Analyzing IBS to Identify Biomarkers and Microbiome Signatures

Overview

About this study

Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to understand the relationship between gut microbiome, vitamin D levels, host gene expression and IBS-D symptoms that could ultimately be used as a testing platform for treatment and prevention.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

IBS-D subjects:
- Patients who fulfill IBS-D criteria, without causes of active inflammation.
- active symptoms for at least 2 months
- diagnosed at least 6 months prior to enrollment
Healthy Control:
- Healthy control patients should have no active infection or inflammation.

Exclusion criteria:

does not meet inclusion criteria
will not participate in blood draw, stool sample donation, or endoscopy
history of acute illness within 3 months of testing
any fecal transplant history

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Amy Foxx-Orenstein, D.O.	Closed for enrollment

Mayo Clinic Location

Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Amy Foxx-Orenstein, D.O.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials